Acurx Pharmaceuticals Inc ACXP released Phase 2b results showing 100% of C. difficile Infection (CDI) patients who had clinical cure (CC) with ibezapolstat,…
In a total of 26 ibezapolstat-treated patients in Phases 2a and 2b, the Clinical Cure rate is 96% Meets protocol primary objective of assessing the primary.
(MENAFN - PR Newswire) In a total of 26ibezapolstat-treated patients in Phases 2a and 2b, the Clinical Cure rate is 96% Meets protocol primary objective of assessing the primary efficacy . .